Drug Discovery World

FEBRUARY 19, 2024

Financial landscape In 2023, life science companies experienced a significant decrease in funding, particularly seed funding for early-stage drug development. Throughout 2023, oncology and rare disease indications consistently dominated the pipeline for advanced therapies, and this trend is expected to continue in 2024.

Drug Development 147

Drug Development Small Molecule Drugs Therapies 147

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . This includes therapies against the nuclear receptor ROR?t,

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

Drug Discovery World

FEBRUARY 5, 2024

Opening keynote Following a change to the schedule, Juliet Williams of Kymera Therapeutics launched the event with a popular keynote talk ‘Solving Big Problems with Small Molecule Degraders’. Life sciences and diagnostics company Revvity showcased over 40 products at SLAS2024, alongside new branding.

Small Molecule 162

Small Molecule Assay Development Production Science 162

Covalent Modifiers

AUGUST 14, 2024

Rullo Molecular Therapy 2024 DOI: [link] Proximity-induction of cell-cell interactions via small molecules represents an emerging field in basic and translational sciences. Lake, Galina Denisova,Joanne A. Hammill,Jonathan L. Bramson, Anthony F.

Small Molecule 65

Small Molecule Engineering Science Therapies 65

Drug Discovery World

JANUARY 17, 2023

The study, led by OSU Associate Professor of Pharmaceutical Sciences Gaurav Sahay, Oregon State doctoral student Marco Herrera-Barrera, and Oregon Health & Science University Assistant Professor of Ophthalmology Renee Ryals, was published in Science Advances. . Limitations of AAV gene therapy .

Small Molecule 246

Small Molecule Pharmacy RNA Packaging 246

Drug Discovery World

OCTOBER 21, 2022

While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US 1 ), outcomes are still poor in certain cancers that do not respond to standard therapies. 3D bioprinted breast cancer tumours.

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Discovery World

APRIL 5, 2024

Neurosterix has launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures. The company will acquire Addex’s allosteric modulator discovery technology platform.

Small Molecule 130

Small Molecule Therapies Treatment Science 130

Drug Discovery World

AUGUST 16, 2023

Over the next two decades, it is quite possible that most new drugs approved could be based on some form of RNA, whether it be through its delivery or targeting the molecule itself. The post Junk DNA: How the dark genome is changing RNA therapies appeared first on Drug Discovery World (DDW).

RNA 130

RNA DNA Therapies Small Molecule 130

Covalent Modifiers

JUNE 24, 2024

Rullo, Molecular Therapy: Oncology , 2024 , 200842, [link] Proximity-induction of cell-cell interactions via small molecules represents an emerging field in basic and translational sciences. Lake, Galina Denisova, Joanne A. Hammill, Jonathan L. Bramson, Anthony F.

Small Molecule 52

Small Molecule Engineering Science Therapies 52

Science Daily: Pharmacology News

NOVEMBER 30, 2023

Researchers have succeeded in restoring lost brain function in mouse models of stroke using small molecules that in the future could potentially be developed into a stroke recovery therapy.

Small Molecule 122

Small Molecule Therapies Research 122

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

LifeSciVC

APRIL 2, 2024

The quality of science – and the ability to distinguish it from other approaches – was the entry ticket to serious engagement. The science presents an opportunity and a challenge for us at Sionna. The science presents an opportunity and a challenge for us at Sionna. That science resonates with investors.

Science 68

Science Small Molecule International Clinical Development 68

Covalent Modifiers

JANUARY 29, 2024

3c01835 Building on recent advances in peptide science, medicinal chemists have developed a hybrid class of bioconjugates, called peptide–drug conjugates, that demonstrate improved efficacy compared to peptides and small molecules independently. Moore Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.3c01835

Small Molecule 62

Small Molecule Drugs Science Disease 62

DrugBank

MAY 15, 2024

This method was more about serendipity than science. Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. One approach is to look beyond the traditional drug molecule.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Drug Target Review

JUNE 15, 2023

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing. It is somewhat like how PROTACs have changed the perspective on what is a tractable therapeutic target.

RNA 96

RNA Small Molecule Disease Assay Development 96

Drug Discovery World

MAY 1, 2024

Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab) 1. These enable researchers to better manipulate biological molecules or identify the best candidates to progress to the next stage of development.

FDA Approval 147

FDA Approval Therapies FDA Molecular Biology 147

Drug Discovery World

APRIL 5, 2023

CBC members are selected in five-year cycles and chosen for their knowledge and expertise in small molecule drug discovery and high-level capabilities to advance projects from target validation to clinical candidate selection.

Small Molecule 130

Small Molecule Cell Biology Laboratories Engineering 130

Drug Hunter

JUNE 11, 2023

Small molecule drugs make up most of the drugs we take conveniently as pills, including painkillers like ibuprofen (Advil), antibiotics like penicillin and amoxicillin, or cholesterol-lowering drugs like atorvastatin (Lipitor). The small molecules drugs of today look nothing like the molecules of the 1970s.

Small Molecule 147

Small Molecule Pharmaceuticals Engineering Treatment 147

The Pharma Data

JUNE 22, 2023

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc. .–(BUSINESS to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc.

Marketing 40

Marketing Therapies Small Molecule Science 40

Broad Institute

OCTOBER 4, 2023

By Allessandra DiCorato October 4, 2023 Credit: AbbVie The new small molecule inhibitor (green) sits inside the PTPN2 protein, where acidic sites are marked in red and basic sites are marked in blue. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.

Small Molecule 128

Small Molecule Clinical Trials Engineering Medical Schools 128

Drug Discovery World

APRIL 27, 2023

In 2021, Savills put together a report on the regional hubs attracting science/pharma investment 1. The Boston Globe headline 3 , ‘Life sciences is poised to be Boston’s dominant industry. Over 450 life science companies including top pharmaceutical manufacturers are concentrated in the region.

Small Molecule 130

Small Molecule Science Drugs FDA Approval 130

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science. We are eager to delve deeper into this research path and its potential clinical utility,” stated Dr Oh.

DNA 130

DNA Small Molecule Science Treatment 130

Drug Discovery World

APRIL 11, 2023

By bridging the gap and bringing world-leading AI researchers into the life sciences, we have the opportunity to create safer and more effective therapeutics for a broad range of diseases.” We will also see improved gene therapies and advanced CRISPR guide RNA design tools. It is excellent timing to combine these technologies.”

RNA 130

RNA Small Molecule Engineering Disease 130

Drug Discovery World

APRIL 6, 2023

from Fabien Vincent, Pfizer, Groton, US High content phenotypic and pathway profiling identifies novel drug mechanisms-of-action tailored towards cancers of unmet need by Neil Carragher, University of Edinburgh, Edinburgh, UK Functional genomics as an enabling tool for phenotypic screening by Matthew Garnett Chemistry to the Clinic: Part 1-3: (..)

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

Drug Discovery World

DECEMBER 26, 2023

Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis’ hereditary angioedema (HAE) drug candidate donidalorsen in Europe. His research focuses on immunotherapies for patients with breast cancer.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

Drug Discovery World

JANUARY 15, 2024

Jennifer Swantek, Director of the Foundation’s IBD Therapeutics Incubator programme, said: “We’re eager to deliver much needed, differentiated therapies to Crohn’s disease and ulcerative colitis patients as soon as possible.” of Perspective’s shares for up to $33 million.

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

Drug Discovery World

APRIL 4, 2023

The FDA approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

FDA 130

FDA FDA Approval Small Molecule Therapies 130

The Pharma Data

NOVEMBER 15, 2020

In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma. The company hopes to follow vibegron to the market with URO-902, a novel gene therapy for patients whose OAB has eluded oral pharmacologic therapy.

Science 52

Science Small Molecule FDA Approval FDA 52

Drug Discovery World

MAY 13, 2024

Key to this is the ability to rapidly determine protein structures alone and in combination with antibodies or small molecules. With that information, researchers can map sequence changes to the spike protein to assess whether there are obvious concerns with vaccine coverage or antibody therapies.

Vaccine 147

Vaccine Virus Small Molecule Disease 147

The Pharma Data

APRIL 22, 2023

While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation. The results are published in the Proceedings of the National Academy of Sciences (PNAS).

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

Drug Target Review

NOVEMBER 6, 2023

2 It is this complexity that necessitates powerful, targeted combination therapies. 4, 5 More recently, new combination regimens have emerged that incorporate targeted therapies to treat a variety of blood cancers, including multiple myeloma (MM), chronic lymphocytic leukaemia (CLL) and acute myelogenous leukaemia (AML).

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

Precision for Medicine

JUNE 26, 2023

Baseline Control’s expertise will become part of Project Farma, Precision for Medicine’s existing biomanufacturing strategy and execution group, expanding the scope of its manufacturing solutions for life science companies and driving greater speed and efficiency in bringing new drugs to market. For more information, visit projectfarma.com.

Science 40

Science Small Molecule Clinical Research Engineering 40

Drug Target Review

MAY 6, 2024

Luckily, my love for science remained. The clinical efficacy of BRAF inhibitors, like most other targeted cancer therapies, is inevitably limited by resistance development. We found that, indeed, cancer’s earliest defence mechanisms are triggered almost immediately after exposure to a targeted cancer therapy.

Science 105

Science Therapies Small Molecule Clinical Trials 105

Drug Discovery World

NOVEMBER 1, 2022

The Sector Snapshot 2022 was commissioned by AusBiotech, an Australian industry body representing and advocating for organisations doing business in and with the global life sciences economy 1. Another key figure outlined by AusBiotech is that Victoria and New South Wales are home to 73% of the life science sector.

Drugs 130

Drugs Science Therapies Clinical Trials 130

Olympian Clinical Research

MAY 6, 2024

As medical understanding grew, so did the sophistication of the therapies. These targeted therapies revolutionized treatment, offering relief to severe cases by specifically addressing the underlying immune responses causing the disease.

Treatment 52

Treatment Small Molecule Immune Response Clinical Research 52